Development, optimization and implementation of a centralized metabolic soft spot assay.

Area of Science:

• Drug Discovery and Development
• Medicinal Chemistry
• Pharmacokinetics

Background:

• High clearance is a significant challenge in drug discovery, often leading to suboptimal drug candidates.
• Metabolic instability can prematurely terminate promising drug development programs.
• Efficient identification of metabolic liabilities is crucial for successful drug optimization.

Purpose of the Study:

• To develop a centralized assay for identifying metabolic soft spots in drug candidates.
• To provide a high-capacity and rapid turnaround solution for metabolic optimization needs within a drug discovery organization.
• To support project teams in mitigating drug instability and understanding structure-metabolism relationships.

Main Methods:

• An integrated quantitative/qualitative approach was employed.
• Orthogonal sample-pooling methodology and software-assisted structure elucidation were utilized.
• Major metabolic soft spots were generated in liver microsomes (rodent and human) in batch mode, with kinetics of parent disappearance and metabolite formation determined within one week.

Main Results:

• A centralized metabolic soft spot identification assay was successfully developed.
• The assay demonstrated adequate capacity and turnaround time to support organizational metabolic optimization needs.
• The assay has been implemented and is actively supporting drug discovery projects.

Conclusions:

• The developed assay effectively identifies metabolic soft spots, a critical step in drug discovery.
• The assay has a positive impact on discovery project teams by mitigating drug instability.
• The assay facilitates the establishment of crucial structure-metabolism relationships, guiding medicinal chemistry efforts.